Compare
Pit 2–4 stocks against each other: U-Score, pillars, fundamentals, and normalized price history. Same universe, same methodology, one view.
| Metric | LALPATHLAB Dr. Lal Path Labs Ltd. Pharma · Small | NEULANDLAB Neuland Laboratories Limited Pharma · Small | ASTRAZEN AstraZeneca Pharma India Limited Pharma · Small | PPLPHARMA Piramal Pharma Limited Pharma · Small |
|---|---|---|---|---|
| Final Score | 49 | 48 | 42 | 24 |
| Verdict | FAIR VALUE | FAIR VALUE | WATCHLIST | OVERVALUED |
| Style | Premium Compounder | Financial Turnaround | WATCHLIST | OVERVALUED |
| Piotroski | 8/9 | 8/9 | 6/9 | 5/9 |
| Valuation | 0/30 | 0/30 | 0/30 | 5/30 |
| Growth | 15/25 | 17/25 | 12/25 | 3/25 |
| Quality | 15/20 | 14/20 | 14/20 | 0/20 |
| Balance Sheet | 10/15 | 8/15 | 10/15 | 6/15 |
| Cash Flow | 4/10 | 4/10 | 3/10 | 7/10 |
| Price | ₹1,565 | ₹17,200 | ₹8,453 | ₹168.87 |
| P/E | 49.20 | 59.80 | 112.00 | — |
| P/B | 10.31 | 11.61 | 24.64 | 2.69 |
| ROE | 22.50% | 21.40% | 23.30% | -3.58% |
| ROCE | 28.30% | 26.60% | 29.30% | 2.69% |
| Debt / Equity | 0.08 | 0.16 | 0.13 | 0.70 |
| FCF Yield | 0.83% | — | 0.02% | 3.76% |
| Dividend Y | 0.91% | 0.20% | 0.37% | 0.08% |
| Altman Z | 9.03 | 8.27 | 9.08 | 2.71 |
| Promoter % | 53.21% | 32.63% | 75.00% | 34.85% |
| Mkt Cap (₹Cr) | 25931.00 | 21762.00 | 21500.00 | 22013.00 |
| Graham # | ₹318.89 | ₹3,053.89 | ₹767.47 | — |
| Fair PE | 42.0 | 42.0 | 42.0 | 0.7 |
| MoS % | -23.7% | -44.4% | -168.3% | — |
Normalized price (3-year, indexed to 100)
Higher line = better relative performance from startLALPATHLAB51
NEULANDLAB125
ASTRAZEN116
PPLPHARMA60